Otsuka Pharmaceuticals Seeks Cirrhosis-related Fluid Retention Indication For Samusca
This article was originally published in PharmAsia News
Executive Summary
Otsuka Pharmaceuticals announced Aug. 1 it has filed an application for an additional indication of cirrhosis-related fluid retention for the vasopressin V2 receptor antagonist Samusca.